JEEP isn't only endo concern. ERP would like a word.....

Status
Not open for further replies.
https://krуsia0430.suspicious-link-...rp?r=1d5ydq&utm_medium=ios&triedRedirect=true
 
Oh, this is interesting. The lying machine says the 'y' is different. Anyway, if you Google "the Trouble with ERP some lady & her AI ghostwriter," it's the first result.

Edit: lulz, and the filters are catching me on the name, I give up.
 

Attachments

  • Screenshot 2026-04-19 11.21.17 AM.webp
    Screenshot 2026-04-19 11.21.17 AM.webp
    27.5 KB · Views: 12
"This started with a customer-led group test involving roughly 80–85 people. Participants bought ERP products themselves, pooled samples, voted on which peptides to send, and organised independent Janoshik testing under the deliberately neutral label “Strong Like Bull” (SLB) so the COAs could not easily be reused by ERP for marketing.

Around 12 ERP peptides were tested and although most products came back acceptable on purity, one product stood out: SS31 50mg. That result showed 44.10 mg, which is about 11.8% underfilled, and also raised an endotoxin concern."

Google ("the trouble with ERP" some lady & her AI ghostwriter) and it should show up

https://substackcdn.com/image/fetch/$s_!mH3w!,f_auto,q_auto:good,fl_progressive:steep/https://suspicious-link-removed-post-media.s3.amazonaws.com/public/images/16d24641-e1b6-4084-8460-3a4357874028_1062x385.jpeg
K_R_Y_S_I_A
 
For quality issues, even Uther has been sucking for some things lately regarding purity and endotoxins, with a record amount of endotoxins for NAD+. Uther had ARA-290 at 86% purity. Low purity for SNAP-8 as well (94%). But Uther has been pretty transparent.

It reminds of the zero peptides situation around December 2024 (before my time) where multiple vendors were affected. More recently, the cloudy reta this year from multiple vendors, possibly due to TFA salts (not just vendor BAC).

SRY had a number of quality concerns last spring/summer, like little black specks in vials. Nexaph had a similar issue with the black specks last May.
 
Last edited:
AI Summary of this issue:

TLDR: A community group test caught ERP's SS31 underfilled by ~12% and flagged for high endotoxins. Instead of refunding affected buyers, ERP offered vague future-order credits, dodged accountability with shifting technical explanations, and reportedly banned customers and deleted chat history when they pushed back. Digging deeper revealed a broader pattern: cloudy products, shipping fees added after purchase, discounts pulled back after orders were placed, and policies changed retroactively to minimize refunds. The article argues the gap between ERP's marketing promises and actual customer experience is substantial and consistent.


Summary: "The Trouble with ERP" (some lady & her AI ghostwriter, April 19, 2026)

A community-organized group test involving roughly 80-85 participants exposed a cascade of product, policy, and customer service problems at peptide vendor ERP. Here are the key issues raised:

The Triggering Event: SS31 Testing

An independent third-party Janoshik test of ERP's SS31 50mg vials showed only 44.10mg actual content, roughly 11.8% underfilled. More seriously, the vials also returned endotoxin levels above the assay's validated reporting range, with an estimated value of 26.790 EU/vial. The group used a neutral label ("Strong Like Bull") on samples specifically to prevent ERP from co-opting the COAs for marketing.

ERP's Response Pattern to the SS31 Result

Rather than offering a straightforward refund or replacement, ERP responded with a series of shifting explanations:

  • Overfill claims (products are supposedly filled at 1.25x), suggesting low test results reflect product characteristics rather than true underfill
  • Suggestions that high content causes poor dissolution, making test results unreliable
  • Exclusion of endotoxin from warranty coverage entirely, citing cost and potential impact on peptide activity as justification for not meeting stricter standards
  • Resolution offered was only a vague, undefined future-order credit, not a refund
One buyer who pressed for a full refund was met with a laughing emoji in response. When they escalated to chargeback threats, they were reportedly banned and their chat messages deleted.

Broader Product Issues

  • SLU-PP-332: Reported as cloudy on reconstitution. ERP first blamed the buyer's BAC water, then reversed to claim the product is naturally turbid. The real issue, not disclosed upfront, is that SLU-PP-332 likely requires DMSO-based solvent to dissolve properly, making it unsuitable for general use without specific guidance.
  • MOTS-c: Reconstituted clear, but turned cloudy after 24 hours refrigerated, suggesting post-reconstitution instability.
  • Other buyers reported additional undisclosed or unresolved cloudy product issues.
Shipping and Pricing Policy Complaints

Multiple buyers described terms changing after orders were already placed or in motion:

  • A Canada-bound buyer was switched from FedEx to Canada Post after the order was placed; the shipping cost difference was only offered as a future-order credit.
  • A buyer qualifying for free shipping was later told their location was a "remote area" and hit with an unexpected $85+ surcharge after the order was underway.
  • A large-order buyer was promised a 4% discount, which was quietly revised down to 3% after committing.
  • A seized order buyer was originally promised full refund or reshipment, then retroactively told a policy change required either 50% payment to reship or a 30% refund.
The "Rolling Problems Forward" Pattern

Several buyers described a recurring dynamic where unresolved issues from one order were acknowledged but not actually fixed, only folded into the next purchase as partial credit or conditional resolution, incentivizing repeat orders rather than clean refunds.

Attribution Deflection

Once the SS31 evidence was presented publicly, ERP shifted to questioning whether the tested product could even be attributed to them, pointing to the neutral SLB label, absence of ERP branding on the COA, and alleged cap color discrepancies as grounds for doubt.

Chat Moderation and Narrative Control

The article claims that shortly after a public warning summarizing the issues was posted, bot accounts appeared in the relevant chat to flood and bury the complaints. It also alleges ERP has deleted negative COAs and banned customers who pushed for refunds, with at least one confirmed case where a buyer was banned and chat history removed after escalating to a chargeback threat.

The Gap Between Marketing and Reality

ERP's stated promises include: a dedicated quality inspection department, products only sold after passing QC, full refunds available for purity/quality failures, lab-tested products, and a stocked U.S. warehouse. The article argues the documented experiences systematically contradict each of those claims.

Bottom Line

The article frames SS31 as the crack that opened a much broader picture: a vendor pattern of shifting explanations, post-sale policy changes, refusal to issue clean refunds, and active suppression of public complaints. The "best" outcome any affected buyer received was a 20% future-order credit, which the author wryly notes made that buyer "the lucky one."
 
⚠️Oops! Something went wrong!
The requested post could not be found.

Edit and now your post is back. ¯\_ (ツ)_/¯
 
Last edited:
I have Orange top ERP T30 out for endo right now. I don't think it is from the same supply chain as JEEP (although ERP is definitly the same as WBS) and the cap does not have a ridge but the endo problem seems to be growing (or its one of those things that was always there and we are just not seeing it becuse we are looking at it harder).
 
The same blog has an article on the cloudy reta from TFA salts:

A newer discussion around ERP linked R20 kits suggests the issue may be spreading more widely than many buyers assume.

Users described vials that turned cloudy immediately with Hospira BAC, while others from the same broader source stream reportedly remained fine. The explanation circulating was residual TFA salts left behind during finishing, not a failed sequence, not a classic purity issue, but a compatibility problem that only reveals itself during reconstitution.
Click to expand...
The harder truth is this;

A peptide can be chemically correct and still be practically wrong.

And right now, Retatrutide is forcing the grey market to confront something it has largely ignored:

Passing a lab test is not the same as performing properly in solution.

The lab says it’s fine.

The vial says it isn’t.

And right now, the vial is telling the more important story.
Click to expand...
From the comments:

You’re right that Reta is the ultimate stress test for the grey market. Because it is larger and more chemically modified than Tirzepatide, it has more "arms" (amino acid side chains) that can unfold or clump if the environment isn't perfect.

It exposes "sloppy" finishing—specifically high salt/TFA loads—that simpler peptides might be able to mask.
Click to expand...
 

Attachments

Last edited:
RetCurious said:
Sounds like ERP is one step from an exit scam finally.
Click to expand...
I feel like there's so much legitimate profit to be made in this space. Why do some vendors insist on cheating people out of pennies instead of seeing the pounds that could be made by establishing themselves as the "goto" vendor for quality. It seems to be an issue with many Chinese companies--not just peptide sellers.

And how many newly-announced vendors that we see are just a rebrand of an exit scam vendor?
 
FartfulCodger said:
I feel like there's so much legitimate profit to be made in this space. Why do some vendors insist on cheating people out of pennies instead of seeing the pounds that could be made by establishing themselves as the "goto" vendor for quality. It seems to be an issue with many Chinese companies--not just peptide sellers.

And how many newly-announced vendors that we see are just a rebrand of an exit scam vendor?
Click to expand...

This really is a big part of what informs my own personal to-buy-from criteria (which neither Jeep nor ERP ever met so I don't use them):

Known to the grey community for > 1 year
Has US warehouse, or at least the product what is shipped to me will be shipped from a US address
No significant scandals in the past six months
No significant scandals EVER that weren't handled to the satisfaction of the community in general
Has never had a full on fuck-you fight with a customer in a public space
Well spoken-of in the community in general
Does not carry AAS

That takes me down to exactly one Chinese vendor at the time of this posting (don't DM me, I've posted about them and reviewed them in the past) and a few group buys or vendors who say they're group buys but are technically vendors at this point. Which is fine.
 
Seems like between Christmas and CNY their product and production go to 💩 . Hopefully by fall it's back on track again just in time to repeat the pattern.
The links not working are probably another site "Easter egg"
 
Calm Logic said:
For quality issues, even Uther has been sucking for some things lately regarding purity and endotoxins, with a record amount of endotoxins for NAD+. Uther had ARA-290 at 86% purity. Low purity for SNAP-8 as well (94%). But Uther has been pretty transparent.

It reminds of the zero peptides situation around December 2024 (before my time) where multiple vendors were affected. More recently, the cloudy reta this year from multiple vendors, possibly due to TFA salts (not just vendor BAC).

SRY had a number of quality concerns last spring/summer, like little black specks in vials. Nexaph had a similar issue with the black specks last May.
Click to expand...
Isnt there a R15 issue too? Affecting erp and at least 3 other vendors.... only time JEEP told the truth was when they said raws are getting shitty and scarce....
 
Everything that’s coming out: ERP, Jeep, R20 kits, Uther, SRY, Nexaph, cloudy Reta, TFA salts, isn’t a series of isolated incidents. It’s a pattern.

And the uncomfortable truth is that these issues originate upstream, in environments with no real quality control: no endotoxin testing, no residual solvent checks, no quantified TFA, no stability work.

So when a batch shows sloppy finishing, sky‑high TFA or immediate precipitation, it isn’t a surprise: it’s what happens when QA doesn’t exist.

Vendors don’t always know the technical details, but they receive the batches, see the differences, see the feedback, see the same problems repeat. It’s hard to believe everything only becomes visible when the customer opens the vial.

That’s why “The lab says it’s fine. The vial says it isn’t.” is the key line: purity and a COA aren’t enough anymore.

Retatrutide is simply exposing what was already there: sloppy finishing, residues, TFA salts, endotoxins, underfills. It’s the stress test that forgives nothing.

And here’s the truth no one likes to say: in the grey market there are no truly “serious vendors.”

There are only two categories:
those trying to stay in business and those trying to cash out before disappearing.

The first group are the unicorns. 🦄 The second is the norm: thin margins, no real QA, no production testing, no stability. And when a problem appears, the priority isn’t fixing it: it’s containing it.

That’s why we keep seeing the same script: blame shifting, wiped chats, forced reships, COAs waved like shields.

It’s not individual malice: it’s the business model of the Chinese grey market.

And in the end, the vial tells the story long before the COA does.
 
Status
Not open for further replies.

Trending Topics

Latest Posts

Forum Statistics

Threads
17,727
Posts
184,113
Members
59,566
Newest
donnydon
Back
Top Bottom